These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1312194)

  • 41. Prostacyclin-mediated protection by angiotensin-converting enzyme inhibitors against injury of aortic endothelium by free radicals.
    Liao DF; Chen X
    Cardioscience; 1992 Jun; 3(2):79-84. PubMed ID: 1379480
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Release of endothelium-derived relaxing factor (EDRF) from cultured vascular endothelial cells depends on extra- and intracellular Ca2+ concentrations].
    Korenaga R
    Hokkaido Igaku Zasshi; 1993 Sep; 68(5):744-54. PubMed ID: 8225180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Freshly harvested endothelial and mononuclear cells: comparison to cells in culture.
    Bing RJ; Dudek R; Conforto A
    In Vitro Cell Dev Biol Anim; 1993 May; 29A(5):353-5. PubMed ID: 8314728
    [No Abstract]   [Full Text] [Related]  

  • 44. Modulation of human endothelial cell tetrahydrobiopterin synthesis by activating and deactivating cytokines: new perspectives on endothelium-derived relaxing factor.
    Schoedon G; Schneemann M; Blau N; Edgell CJ; Schaffner A
    Biochem Biophys Res Commun; 1993 Nov; 196(3):1343-8. PubMed ID: 8250889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture.
    Cocks TM; Angus JA; Campbell JH; Campbell GR
    J Cell Physiol; 1985 Jun; 123(3):310-20. PubMed ID: 3886674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins.
    Chin JH; Azhar S; Hoffman BB
    J Clin Invest; 1992 Jan; 89(1):10-8. PubMed ID: 1309534
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of chemical mediators released by the endothelium in the control of the cardiovascular system.
    Vane JR; Botting RM
    Int J Tissue React; 1992; 14(2):55-64. PubMed ID: 1399322
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vasoactive mediators derived from the endothelium.
    Botting R; Vane JR
    Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():11-4. PubMed ID: 2514650
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.
    Wohlfart P; Malinski T; Ruetten H; Schindler U; Linz W; Schoenafinger K; Strobel H; Wiemer G
    Br J Pharmacol; 1999 Nov; 128(6):1316-22. PubMed ID: 10578147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Recent advances in EDRF research].
    Shikano K
    Nihon Rinsho; 1992 Jun; 50(6):1430-6. PubMed ID: 1518161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Kinins act on B1 or B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells.
    D'Orléans-Juste P; de Nucci G; Vane JR
    Br J Pharmacol; 1989 Apr; 96(4):920-6. PubMed ID: 2545298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does halothane interfere with the release, action, or stability of endothelium-derived relaxing factor/nitric oxide?
    Blaise G; To Q; Parent M; Lagarde B; Asenjo F; Sauvé R
    Anesthesiology; 1994 Feb; 80(2):417-26. PubMed ID: 8311324
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 17 beta-Estradiol inhibits flow- and acute hypoxia-induced prostacyclin release from perfused endocardial endothelial cells.
    Redmond EM; Cherian MN; Wetzel RC
    Circulation; 1994 Nov; 90(5):2519-24. PubMed ID: 7955210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fendiline and calmidazolium enhance the release of endothelium-derived relaxant factor and of prostacyclin from cultured endothelial cells.
    Busse R; Lückhoff A; Winter I; Mülsch A; Pohl U
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Jan; 337(1):79-84. PubMed ID: 3285226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potentiation of the vasorelaxant activity of nitric oxide by hydroxyguanidine: implications for the nature of endothelium-derived relaxing factor.
    Zembowicz A; Swierkosz TA; Southan GJ; Hecker M; Vane JR
    Br J Pharmacol; 1992 Dec; 107(4):1001-7. PubMed ID: 1281716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide.
    Myers PR; Minor RL; Guerra R; Bates JN; Harrison DG
    Nature; 1990 May; 345(6271):161-3. PubMed ID: 2110626
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP.
    Alheid U; Reichwehr I; Förstermann U
    Eur J Pharmacol; 1989 May; 164(1):103-10. PubMed ID: 2546782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective inhibition of agonist-induced but not shear stress-dependent release of endothelial autacoids by thapsigargin.
    Macarthur H; Hecker M; Busse R; Vane JR
    Br J Pharmacol; 1993 Jan; 108(1):100-5. PubMed ID: 8428199
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Significance of endothelial cells for the regulation of the tone of smooth muscle--formation of an endothelial, relaxing factor].
    Förstermann U
    Z Kardiol; 1986 Oct; 75(10):577-83. PubMed ID: 2878541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytokine production from freshly harvested human mononuclear cells attached to plastic beads.
    Bing RJ; Dudek R; Kähler J; Narayan KS; Ingram M
    Tissue Cell; 1992; 24(2):203-9. PubMed ID: 1589869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.